<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80622">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01926847</url>
  </required_header>
  <id_info>
    <org_study_id>16787</org_study_id>
    <secondary_id>2013-001899-38</secondary_id>
    <nct_id>NCT01926847</nct_id>
  </id_info>
  <brief_title>Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator</brief_title>
  <acronym>DIGIT</acronym>
  <official_title>Single Dose, Double-blind, Placebo-controlled, Single Center, Randomized Cross-over Study to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetic Properties of BAY63-2521 After Oral Dosing in 20 Patients With Raynaud's Phenomenon (RP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with Raynaud's phenomenon suffer from painful attacks triggered by stress or cold
      causing acute lowering of blood flow through the digits. In this trial the safety and
      efficacy as well as the effect of one dose of the sGC stimulator Riociguat on digital blood
      flow will be measured during a cold exposure test in patients suffering from Raynaud's
      phenomenon. Measurements of two periods will be compared: in one period the patient will be
      given active drug and in the other period  a placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
  <primary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>5 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>5 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulse rate</measure>
    <time_frame>5 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of participants showing changes during clinical laboratory and hematology assessment</measure>
    <time_frame>From baseline to 5 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration at 2 h after riociguat administration</measure>
    <time_frame>After 2 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Placebo corrected change in digital blood flow at room temperature, measured by Laser Doppler Perfusion Imaging</measure>
    <time_frame>At baseline and after 2h</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Placebo corrected change in digital blood flow during cold exposure, measured by Laser Doppler Perfusion Imaging</measure>
    <time_frame>At baseline and after 2h</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Raynaud Disease</condition>
  <arm_group>
    <arm_group_label>Riociguat+Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomization order 1: first single oral dose of 2 mg BAY63-2521, then matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo+Riociguat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomization order 2: first matching placebo, then single oral dose of 2 mg BAY63-2521</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riociguat (Adempas, BAY63-2521)</intervention_name>
    <arm_group_label>Riociguat+Placebo</arm_group_label>
    <arm_group_label>Placebo+Riociguat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Riociguat+Placebo</arm_group_label>
    <arm_group_label>Placebo+Riociguat</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients suffering from Raynaud's phenomenon diagnosed at least ≥1 year before
             beginning of the study of the following origin:

               -  idiopathic (primary)

               -  limited cutaneous Scleroderma associated

               -  diffuse cutaneous Scleroderma associated

               -  mixed connective tissue disease associated

        Exclusion Criteria:

          -  Patients taking medication interfering with the digital flow measurement such as
             calcium channel blockers (CCB), phosphodiesterase 5 (PDE5) inhibitors, endothelin
             receptor antagonists (ERA), Nitrates

          -  Smokers

          -  Systolic blood pressure (SBP) below 105mmHg at rest
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <email>clinical-trials-contact@bayerhealthcare.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Köln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 16, 2014</lastchanged_date>
  <firstreceived_date>August 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Digital ischemia</keyword>
  <keyword>Raynaud's phenomenon</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Raynaud Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
